Showing results (1491-1500 of 1,639) with videos related to

Sort By:
Pageof 164
Plos One|January 27, 2025
Distinguishing benign and malignant myxoid soft tissue tumors: Performance of radiomics vs. radiologistsJoshua M Lawrenz, Can Cui, Samuel R Johnson, et al.
Frontiers in Cardiovascular Medicine|October 28, 2022
Serum peptidomic screening identified circulating peptide biomarkers predictive for preeclampsiaShenglong Zhao, Chenghong Yin, Yanhong Zhai, et al.
Optics Express|June 13, 2014
A low-power, high-speed, 9-channel germanium-silicon electro-absorption modulator array integrated with digital CMOS driver and wavelength multiplexerA V Krishnamoorthy, X Zheng, D Feng, et al.
Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery]|September 27, 2025
[One-year outcomes of a novel domestic transcatheter aortic valve system in severe aortic stenosis: a multicenter cohort study]Y H Li, J W Zhou, L Wei, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 5, 2015
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)C Zhou, Y L Wu, G Chen, et al.
European Journal of Neurology|April 14, 2020
Diagnostic potential of urinary monocyte chemoattractant protein-1 for Alzheimer's disease and amnestic mild cognitive impairmentY Xu, Y-Y Shen, X-P Zhang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2013
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)G Chen, J Feng, C Zhou, et al.
Theranostics|February 23, 2024
Global metabolomics revealed deviations from the metabolic aging clock in colorectal cancer patientsLong Zhang, Shaobo Mo, Xiurui Zhu, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|May 21, 2025
Metabolic pathway alterations in cerebrospinal fluid as diagnostic biomarkers for primary central nervous system lymphomaJingjing Ma, Di Wang, Xiangyu Li, et al.
Frontiers in Immunology|August 15, 2024
Targeted multiplex validation of CSF proteomic biomarkers: implications for differentiation of PCNSL from tumor-free controls and other brain tumorsJingjing Ma, Zhiguang Lin, Yaqi Zhang, et al.
Pageof 164